Samsung Biologics to acquire Swiss CDMO for 2.7 trillion won in global expansion push

The $1.8 billion deal signals aggressive capacity building for the South Korean contract manufacturer as it seeks to capture more global biopharma outsourcing demand.

By Handelsavisen Newsroom · Automated 2026-07-20 01:02 UTC · 1 min read

Samsung Biologics has announced plans to acquire a Swiss-based contract development and manufacturing organization (CDMO) for 2.7 trillion won, equivalent to approximately $1.8 billion.

The move marks a significant step in the company’s strategy to expand its global footprint and secure additional production capacity amid rising demand for biopharmaceutical manufacturing services.

5 billion, highlighting the trend of major players bolstering their capabilities through M&A.

The acquisition targets a firm in Switzerland, a hub for pharmaceutical innovation, allowing Samsung Biologics to deepen its presence in the European market.

By integrating a Swiss CDMO, the company aims to leverage local expertise and infrastructure to serve a broader client base, particularly among European and North American biotech firms seeking reliable manufacturing partners.

This deal comes as the broader CDMO sector sees increased consolidation.

Novartis recently agreed to acquire UK-based biotechnology company Myricx Bio in a transaction valued at up to $1.5 billion, highlighting the trend of major players bolstering their capabilities through M&A.